RedHill Biopharma (NASDAQ: RDHL) director details RSUs and stock options
Rhea-AI Filing Summary
RedHill Biopharma Ltd. director Reed Kenneth filed an initial ownership report showing equity interests in the company. He holds 10,520 unvested restricted share units, each tied to one American Depositary Share and settled in ordinary shares, plus 2,583 ADSs that are convertible at any time and have no expiration date.
He also holds stock options to purchase 90,000 ordinary shares (equivalent to 9 ADSs) at an exercise price of $4,870 per ADS expiring on March 25, 2030, 150,000 ordinary shares (equivalent to 15 ADSs) at $7,000 per ADS expiring on May 6, 2029, and 250,000 ordinary shares (equivalent to 25 ADSs) at $6,620 per ADS expiring on July 25, 2031. These options are fully vested and exercisable.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Reed Kenneth
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Shares | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
American Depositary Shares — 25,830,000 shares (Direct);
Stock Option (Right to Buy) — 490,000 shares (Direct);
Ordinary Shares — 105,200,000 shares (Direct)
Footnotes (5)
- F1. Represents 10,520 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.
- F2. Represents 2,583 ADSs, which are convertible at any time, at the holder's election and have no expiration date.
- F3. Represents stock option to purchase 90,000 Ordinary Shares (equivalent to 9 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $4,870 per ADS and the option expires on March 25, 2030.
- F4. Represents stock option to purchase 150,000 Ordinary Shares (equivalent to 15 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,000 per ADS and the option expires on May 6, 2029.
- F5. Represents stock option to purchase 250,000 Ordinary Shares (equivalent to 25 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $6,620 per ADS and the option expires on July 25, 2031.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does the RedHill Biopharma (RDHL) Form 3 filing for Reed Kenneth show?
The Form 3 shows director Reed Kenneth’s initial equity holdings in RedHill Biopharma, including unvested RSUs, American Depositary Shares, and several fully vested stock options. It outlines his current ownership but does not report any recent buy or sell transactions.
How many unvested RSUs tied to ADSs does Reed Kenneth hold in RDHL?
Reed Kenneth holds 10,520 unvested restricted share units, each linked to one American Depositary Share of RedHill Biopharma. These RSUs are subject to time-based vesting conditions and are settled in the company’s ordinary shares once vesting requirements are met.
What stock options does Reed Kenneth hold in RedHill Biopharma and when do they expire?
He holds options for 90,000 ordinary shares expiring March 25, 2030, 150,000 ordinary shares expiring May 6, 2029, and 250,000 ordinary shares expiring July 25, 2031. All these options are fully vested and exercisable under the RedHill 2010 Option Plan.
What are the exercise prices of Reed Kenneth’s RedHill Biopharma (RDHL) stock options?
The options have exercise prices of $4,870 per ADS for 90,000 ordinary shares, $7,000 per ADS for 150,000 ordinary shares, and $6,620 per ADS for 250,000 ordinary shares. Each option is fully vested and can be exercised before its stated expiration date.
Are Reed Kenneth’s stock options in RedHill Biopharma (RDHL) already vested?
Yes. The Form 3 footnotes state that the stock options to purchase 90,000, 150,000, and 250,000 ordinary shares are fully vested and exercisable. This means he can choose to exercise these options at their respective exercise prices before they expire.